Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
January 02 2024 - 8:00AM
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”),
a clinical-stage biotechnology company leading the discovery and
development of the next generation of allosteric small molecule
therapies, today announced that a late-breaking abstract with new
data of GT-02287 in preclinical models of Parkinson’s disease has
been accepted for a platform presentation at the 20th Annual
WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA.
Details of the platform presentation are as
follows:
Title: GT-02287, a clinical
stage GCase enhancer, displays neuroprotection and restores motor
function in preclinical models of Parkinson’s disease following
delayed administrationPresenter: Beatriz
Calvo-Flores Guzman, Ph.D., Gain
TherapeuticsSession: Late-Breaking
ScienceDate and Time: Friday, February 9, 2024,
8:00 a.m. PTRegister: here
About
WORLDSymposium™
WORLDSymposium™ is an annual research conference
dedicated to lysosomal diseases. WORLD is an acronym that stands
for We’re Organizing Research on Lysosomal Diseases. The goal of
WORLDSymposium is to provide an interdisciplinary forum to explore
and discuss specific areas of interest, research and clinical
applicability related to lysosomal diseases. Each year,
WORLDSymposium hosts a scientific meeting presenting the latest
information from basic science, translational research, and
clinical trials for lysosomal diseases.
About Gain Therapeutics,
Inc.
Gain Therapeutics, Inc. is a clinical-stage
biotechnology company leading the discovery and development of next
generation allosteric therapies. Gain’s lead drug candidate
GT-02287, in development for the treatment of GBA1 Parkinson’s
disease, is currently being evaluated in a Phase 1 clinical
trial.
Leveraging AI-supported structural biology,
proprietary algorithms and supercomputer-powered physics-based
models, the company’s SEE-Tx® discovery platform can identify novel
allosteric binding sites on disease-implicated proteins,
pinpointing pockets that cannot be found or drugged with current
technologies. Gain’s unique approach enables the discovery of
novel, allosteric small molecule modulators that can restore or
disrupt protein function. Deploying its highly advanced platform,
Gain is accelerating drug discovery and unlocking novel
disease-modifying treatments for untreatable or difficult-to-treat
disorders including neurodegenerative diseases, rare genetic
disorders and oncology. For more information, please visit
GainTherapeutics.com and follow us on LinkedIn.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements in this press release other than
statements of historical facts are “forward-looking statements”. In
some cases, you can identify these statements by forward-looking
words such as "may," "might," "will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "goal, " "intend,"
"seek, " "potential" or "continue," the negative of these terms and
variations of these words or similar expressions that are intended
to identify forward-looking statements, although not all
forward-looking statements contain these words. Forward-looking
statements in this press release include, but are not limited to,
statements regarding: the development of the Company’s current or
future product candidates including GT-02287 and the potential
therapeutic and clinical benefits of the Company’s product
candidates. These forward-looking statements are based on the
Company’s expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties that could cause the Company’s preclinical and
future clinical development programs, future results or performance
to differ materially from those expressed or implied by the
forward-looking statements. These statements are not historical
facts but instead represent the Company's belief regarding future
results, many of which, by their nature, are inherently uncertain
and outside the Company's control. Many factors may cause
differences between current expectations and actual results,
including the impacts of the post-COVID-19 environment and other
global and macroeconomic conditions on the Company’s business;
clinical trials and financial position; unexpected safety or
efficacy data observed during preclinical studies or clinical
trials, clinical trial site activation or enrollment rates that are
lower than expected; changes in expected or existing competition;
changes in the regulatory environment; the uncertainties and timing
of the regulatory approval process; and unexpected litigation or
other disputes. Other factors that may cause the Company’s actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are identified in
the section titled “Risk Factors,” in the Company’s Annual Report
on Form 10-K filed with the Securities and Exchange Commission on
March 23, 2023 and its other documents subsequently filed with or
furnished to the Securities and Exchange Commission from time to
time. All forward-looking statements contained in this press
release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Investor Contact:
Evan C. Ballantyne, Chief Financial Officer(401)
215-6003eballantyne@gaintherapeutics.com
Media Contact:
Susan SharpeLinnden Communications(919)
602-2330susan@linndencom.com
Gain Therapeutics (NASDAQ:GANX)
Historical Stock Chart
From Apr 2024 to May 2024
Gain Therapeutics (NASDAQ:GANX)
Historical Stock Chart
From May 2023 to May 2024